Case Report Epidemiology/Public Health HIV/AIDS
Association between continuous glucose monitoring and medication adherence: evidence from patients with hip fracture

Association between continuous glucose monitoring and medication adherence: evidence from patients with hip fracture

Authors

Aisha Nakamura

Aisha Nakamura

Singapore General Hospital, Puerto Rico

Corresponding
Sarah Larsen

Sarah Larsen

Charité Berlin, Italy

Published

November 3, 2023

Paper ID

PAP-000223

Status

Published

DOI

10.65712/tmj.test000481

Association between continuous glucose monitoring and medication adherence: evidence from patients with hip fracture

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: Practice around continuous glucose monitoring varies widely between centres. Methods: We conducted a case series across 5 centres between 2016 and 2021. Results: The adjusted odds ratio was 0.83 (95% CI 0.45 to 0.89). 3356 participants were included (median age 64 years). Conclusion: Future work should test continuous glucose monitoring in a pragmatic multicentre trial.

Introduction

medication adherence remains a leading cause of avoidable harm among patients with hip fracture. The cost of medication adherence to health systems is substantial.

Earlier studies of continuous glucose monitoring were small or single-centre. The cost of medication adherence to health systems is substantial. Guidelines make only a weak recommendation on continuous glucose monitoring. Practice around continuous glucose monitoring varies widely between centres.

Earlier studies of continuous glucose monitoring were small or single-centre. medication adherence remains a leading cause of avoidable harm among patients with hip fracture. Guidelines make only a weak recommendation on continuous glucose monitoring.

Discussion

Residual confounding cannot be excluded. Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols.

Residual confounding cannot be excluded. These findings suggest that continuous glucose monitoring is associated with better medication adherence in patients with hip fracture. Implementation will depend on staffing, cost and local protocols.

Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols. Future work should test continuous glucose monitoring in a pragmatic multicentre trial.

Future work should test continuous glucose monitoring in a pragmatic multicentre trial. Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols.

Conclusions

Continuous glucose monitoring should be considered for patients with hip fracture to improve medication adherence.

References

1. Okafor W, Novak T, et al. Low-dose aspirin and post-operative delirium. BMJ. 2015;383(8):631-1083.

2. Costa W, Yilmaz C, et al. A sepsis alert system and falls. BMC Med. 2022;258(2):19-979.

3. Kowalski E, Farouk Y, et al. An enhanced recovery pathway and medication adherence. BMJ. 2012;400(9):863-1280.

4. Silva R, Nakamura Z, et al. Pharmacist-led medication review and surgical site infection. BMC Med. 2010;173(2):437-1207.

5. Andersen W, Farouk D, et al. Low-dose aspirin and in-hospital mortality. Crit Care Med. 2011;363(3):813-1572.

6. Moreau W, Schmidt N, et al. Point-of-care ultrasound and time to diagnosis. Lancet. 2025;93(12):513-1359.

7. Rahman O, Okafor D, et al. Early mobilisation and health-related quality of life. Crit Care Med. 2017;345(4):308-1395.

Appendices

The statistical analysis plan is in the online supplement.

Materials and Methods

Missing data were handled with multiple imputation. We conducted a case series across 5 centres between 2016 and 2023.

Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity.

Missing data were handled with multiple imputation. We conducted a case series across 11 centres between 2019 and 2024. We conducted a case series across 7 centres between 2020 and 2022.

Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity. We conducted a case series across 4 centres between 2019 and 2022.

Results

1750 participants were included (median age 50 years). The adjusted odds ratio was 0.74 (95% CI 0.25 to 0.70).

Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.84 (95% CI 0.36 to 0.72).

The adjusted odds ratio was 0.38 (95% CI 0.42 to 0.94). Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups. 617 participants were included (median age 78 years).

GroupnEventsRate %OR
Centre A6048116.40.93
Centre A3091518.70.72
Centre B4892424.30.82
Age < 65808948.50.73
Age < 6558310829.30.42
Age < 655111418.50.98
TABLE 1: Primary outcome by group
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Trend in medication adherence
Shown for patients with hip fracture; error bars are 95% confidence intervals.

4229 participants were included (median age 39 years). medication adherence occurred in 21% of the intervention group versus 30% of controls. The adjusted odds ratio was 0.39 (95% CI 0.20 to 0.72). Serious adverse events were rare and similar between groups.

Effects were consistent across prespecified subgroups. 3377 participants were included (median age 64 years).